Quick Takeaways
- Peter A. Thompson has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $233,067,428.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Peter A. Thompson
- Location
- New York, NY
- Summary
- The estimated net worth of Peter A. Thompson is at least $233,067,428 dollars as of 04 Feb 2026. Peter A. Thompson is the Director of Sionna Therapeutics, Inc. and owns shares of Sionna Therapeutics, Inc. (SION) stock worth about $157.4M. Peter A. Thompson is the Director, 10%+ Owner of Corvus Pharmaceuticals, Inc. and owns shares of Corvus Pharmaceuticals, Inc. (CRVS) stock worth about $66.74M. Peter A. Thompson is the Director, 10%+ Owner of Edgewise Therapeutics, Inc. and owns shares of Edgewise Therapeutics, Inc. (EWTX) stock worth about $8.93M.
- Signature
- /s/ Peter A. Thompson
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Peter A. Thompson and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Sionna Therapeutics, Inc. ($157,398,695).
- Past-year value change for that position: -$7,763,508.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Peter A. Thompson
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | Director | $157,398,695 | -$7,763,508 | -4.7% | 02 Feb 2026 |
| CRVS | Corvus Pharmaceuticals, Inc. | Director, 10%+ Owner | $66,735,200 | -$4,891,894 | -6.8% | 28 Jan 2026 |
| EWTX | Edgewise Therapeutics, Inc. | Director, 10%+ Owner | $8,933,533 | 16 Jun 2025 | ||
| ALPN | ALPINE IMMUNE SCIENCES, INC. | Director | $0 | 18 May 2024 | ||
| SPRY | ARS Pharmaceuticals, Inc. | Director | $0 | 25 Jun 2025 | ||
| DBTX | Decibel Therapeutics, Inc. | Director, 10%+ Owner | 17 Jun 2022 | |||
| JANX | Janux Therapeutics, Inc. | Director | 14 Jun 2022 | |||
| PMVP | PMV Pharmaceuticals, Inc. | Director, 10%+ Owner | 02 Jun 2021 |
Insider Transactions Reported by Peter A. Thompson:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.